Objective: To study the effects and prognosis of chemotherapy in the treatment of advanced esophageal cancer. Methods: 83 patients with advanced esophageal carcinoma who were treated were analyzed retrospectively. All cases were classified into two groups according to cisplantin regimen (59 cases) or not (24 cases). Results: The overall response rate was 30.0%. The median survival time was 7 months. The 1-year and 2-year survival rates were 37.3% and 7.7% respectively. The response rate of cisplatin regimens (37.3%) was more than that of non-cisplatin regimens (12.5%). Difference was statistically significant, χ2 = 4.98, P = 0.026. The median survival time of patients who were effectively treated by chemotherapy (13 months) was obviously longer than that of patients who were not effectively treated by the chemotherapy (6 months). Difference was statistically significant, log rank value was 7.59, P = 0.005 9. Conclusion: Cisplantin-based regimens should be the first choice of chemotherapy regimens for esophageal carcinoma and survival time was significantly prolonged if the initial chemotherapy was effective.
|Number of pages||3|
|Journal||Chinese Journal of Cancer Prevention and Treatment|
|State||Published - Dec 2008|
- Cisplatin/therapeutic uses
- Esophageal neoplasms/drug therapy
- Paclitaxel/therapeutic uses